Late-onset acute GVHD: clues for endothelial GVHD
نویسندگان
چکیده
منابع مشابه
Advances in predicting acute GVHD.
Acute graft-versus-host disease (GVHD) is a leading cause of non-relapse mortality following allogeneic haematopoietic cell transplantation. Attempts to improve treatment response in clinically-established GVHD have not improved overall survival, often due to the increased risk of infectious complications. Alternative approaches to decrease GVHD-related morbidity and mortality have focused on t...
متن کاملThe Serenity Prayer for acute GVHD.
expression to predict the clinical response to tipifarnib and etoposide. RASGRP1 is a guanine nucleotide exchange factor (GEF) that specifically activates RAS, and Aprataxin is a member of the histine triad family of nucleotide hydrolsases involved in the repair of DNA strand breaks. 3 The two-gene expression ratio (RASGRP1/APTX) was identified by analyzing gene expression profiles in bone marr...
متن کاملPlasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.
We identified plasma biomarkers that presaged outcomes in patients with gastrointestinal graft-versus-host disease (GVHD) by measuring 23 biomarkers in samples collected before initiation of treatment. Six analytes with the greatest accuracy in predicting grade 3-4 GVHD in the first cohort (74 patients) were then tested in a second cohort (76 patients). The same 6 analytes were also tested in s...
متن کاملCurrent and novel therapies in acute GVHD.
Despite improvements in our understanding of transplant immunology and clinical and supportive care, acute graft-versus-host disease (GVHD) remains a clinical challenge and a major cause of morbidity and mortality for patients after allogeneic hematopoietic stem-cell transplantation. While systemic corticosteroid is standard primary therapy for acute GVHD, there is no established standard treat...
متن کاملSteroid-Refractory Acute GVHD: Predictors and Outcomes
Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess of 90%. We sought to identify a subgroup of patients less likely to benefit from initial therapy with corticosteroids as well as the impact of response on day 14 on outcome. Retrospective evaluation was performed of patients with biopsy-proven aGVHD treated with cortic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2016
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2016-09-740951